IMFINZI 50 mg/mL concentrate for solution for infusion
Sponsors
Fundacion GECP, AstraZeneca AB, Intergroupe Francophone De Cancerologie Thoracique, Ideaya Biosciences Inc., Semmelweis University
Conditions
Biliary Tract CancerDLL3 Expressing Tumors Including Small Cell Lung CancerGastroesophageal AdenocarcinomaNon-Small cell lung cancer (NSCLC)Small-cell lung cancerStage III Non Small Cell Lung CancerUnresectable stage III non-small cell lung cancerbladder carcinoma
Phase 1
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)
Not yet recruitingCTIS2025-521639-34-00
Target: 4Updated: 2026-03-27
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
Not yet recruitingCTIS2025-523438-24-00
Target: 35Updated: 2026-07-03
Phase 2
Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02
RecruitingCTIS2025-521251-24-00
Start: 2025-12-01Target: 68Updated: 2025-09-08
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer
Not yet recruitingCTIS2025-522801-39-00
Target: 177Updated: 2026-07-02
IKF-099/D-FLOT-TNT
Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Not yet recruitingCTIS2026-525185-21-00
Target: 66Updated: 2026-07-23
In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint
Not yet recruitingCTIS2026-526251-60-00
Target: 20Updated: 2026-08-31
Phase 3
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
Not yet recruitingCTIS2025-523085-24-00
Target: 27Updated: 2026-03-23
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
Not yet recruitingCTIS2026-525513-31-00
Target: 190Updated: 2026-08-18